Table 1.

Characteristics of RCTs included in this systematic review

Source	Country	Study design	Total, n	Subjects intensity	Age (years) mean (SD)	Baseline MMSE mean (SD)	Intervention	Duration	Risk of bias
Merce [12] 2020	Spain and USA	RCT	322	Mild to moderate	69.0 (7.7)	21.6 (2.6)	PE VS placebo	6 weeks + 12 months (6 weeks dosing period and 12 months observation period)	L, L, L, L, U, U
Sha [32] 2019	USA	RCT	18	Mild to moderate	74.2 (3.84)	19.39 (3.24)	Young plasma infusions VS placebo	14 weeks	L, L, L, U, H, U
NCT00742417 [33] 2017	Spain and USA	RCT	37	Mild to moderate	67.7 (7.9)	21.5 (2.8)	PE VS placebo	21 weeks + 6 months (21 weeks dosing period and 6 months observation period)	L, L, L, U, U, U
Kile [34] 2017	USA	RCT	49	MCI	72.3 (7.56)	26.6 (2.4)	IVIG VS placebo	104 weeks (10 weeks dosing period and 94 weeks observation period)	L, L, L, L, U, U
Relkin [23] 2017	USA and Canada	RCT	390	Mild to moderate	70.3 (9.3)	21.3 (3.2)	IVIG VS placebo	78 weeks	L, L, L, U, H, U
NCT01524887 [24] 2012	USA	RCT	261	Mild to moderate	70.8 (9.0)	NR	IVIG VS placebo	78 weeks	L, U, L, L, L, L
Dodel [35] 2013	Germany and USA	RCT	55	Mild to moderate	70.1 (8.2)	21.5 (5.3)	IVIG VS placebo	24 weeks	L, L, L, L, L, L
Arial [36] 2014	Japan	RCT	16	Mild to moderate	72.6	20.0	IVIG VS placebo	26 weeks (12 weeks dosing period and 14 weeks observation period)	U, U, L, U, U, U

RCT randomized controlled trial, PE plasma exchange, IVIG intravenous immunoglobulin, MCI mild cognitive impairment, NR not reported, MMSE Mini-mental State Examination